Expert Consensus on the Use of Isotretinoin in Rejuvenation: A Delphi Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Isotretinoin, Isotretinoin Adverse Reaction, Rejuvenation. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This expert consensus project explores the role of low-dose isotretinoin as a rejuvenative and preventive strategy for photoaging and sebaceous-driven skin changes. While isotretinoin is traditionally used for acne, increasing clinical experience suggests that carefully selected micro-dose and low-dose regimens may improve skin texture, pore size, sebaceous activity, and overall skin quality, with potential benefits in skin aging and maintenance rejuvenation programs.
Detailed description
This study is a non-interventional, Delphi-based expert consensus project designed to establish recommendations for the use of isotretinoin in skin rejuvenation. While isotretinoin is primarily indicated for acne, accumulating clinical evidence and practitioner experience suggest that low-dose or micro-dose regimens may contribute to improvements in skin texture, fine lines, pore size, sebaceous activity, and overall skin quality. However, standardized guidance on indications, dosing, treatment duration, monitoring, and safety precautions is limited.
A panel of expert dermatologists with practical experience in isotretinoin therapy and skin rejuvenation will be invited to participate in multiple iterative Delphi rounds. Experts will rate agreement with proposed statements using a structured Likert scale. After each round, anonymized feedback will be provided, and statements not reaching consensus will be revised and re-evaluated until stable agreement is achieved.
The final output will consist of consensus-based recommendations reflecting practical, safe, and evidence-informed guidance for dermatologists considering isotretinoin for rejuvenation purposes. The study will also identify areas of uncertainty where further research is needed, supporting the safe expansion of isotretinoin applications beyond acne management.
Primary outcome measures
- Primary Outcome [Time frame: 6-12 weeks]
Secondary outcome measures (1)
- Secondary Outcome [Time frame: 6-12 weeks]
Eligibility criteria
Inclusion criteria
- Board-certified dermatologists or equivalent.
- 5 years clinical experience in dermatology.
Practical experience prescribing isotretinoin, including low- or micro-dose regimens for rejuvenation or acne.
Active engagement in clinical dermatology, teaching, research, or guideline development.
Willingness to participate in all Delphi rounds and provide informed consent.
Exclusion criteria
- Non-dermatology specialists.
Less than 5 years of clinical experience.
Lack of relevant isotretinoin experience.
Significant undisclosed conflict of interest with isotretinoin manufacturers.
Inability to participate in all Delphi rounds.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Egypt · 1 center
- Venus Research Center — Cairo
Identifiers
NCT: NCT07296536 · Isotretinoin-Rejuvenation